Skip to main content


Fig. 3 | BMC Gastroenterology

Fig. 3

From: Multicenter study on hemorrhagic risk of heparin bridging therapy for periendoscopic thromboprophylaxis

Fig. 3

Antithrombotic therapy status at bleeding. Among 21 patients who received heparin as a bridge to anticoagulant medication and experienced post-procedural bleeding, the timing of bleeding was analyzed with the timing classified into five categories from A to E according to the antithrombotic therapy status at bleeding. A, before post-procedural resumption of heparin; B, after resumption of heparin but before resumption of oral antithrombotic therapy; C, during concomitant use of heparin and an anticoagulant; D, during concomitant use of three drugs of heparin, an anticoagulant, and an antiplatelet drug; E, after the end of heparin bridging and during oral antithrombotic therapy. The percentages at the bottom indicate the proportions of patients who had bleeding during the time periods

Back to article page